The tweet was deleted by the author.
But we saved everything 🙂.
Merck received a positive opinion from the European Union's CHMP for a new combination treatment aimed at certain kidney cancer patients, with the development first announced on October 19, 2026. Separately, the stock edges lower on the day, trading at $146.93.
The positive CHMP opinion was first announced on October 19, 2026. Merck announced a positive CHMP opinion for a potential new combination treatment for certain people with kidney cancer in the European Union. According to Rallies, the Welireg-lenvatinib combination reduced the risk of disease progression or death by 26% versus cabozantinib, although overall survival improvement was not statistically significant.
View post on X Loading...
Price is sitting right at support from the Ichimoku Kijun at $146.45. That support holds significance as shares remain above the MA-20, MA-50, and MA-200, preserving a bullish structure on the daily chart. The market has shown a muted reaction, with movements constrained against the prevailing upward bias.
Traders should watch for whether price stays above or drops below the Ichimoku Kijun at $146.45 to assess if the latest development is being absorbed. Price is currently testing this support level without a decisive break. The move has been contained within a narrow range over the past week, but from here, the probability of an upside move over the next five trading days stands at 74%, with a 26% chance of a downside move and an expected trading range of $145.13 to $148.72. A close above $149.31 would confirm buyers are willing to follow through, while a drop below $146.45 would indicate the move is being faded. On the weekly chart, the longer-term picture stays firmly constructive.
Previously it was reported that Merck initiated a major phase 3 clinical trial targeting the prevention of COPD exacerbations in adults with a history of flare-ups. The current positive CHMP opinion for a new kidney cancer combination treatment adds a fresh catalyst to the pipeline, and traders should monitor whether shares can maintain support above the Ichimoku Kijun level at $146.45 for early signs of directional momentum.